Two cases of resectable pancreatic cancer diagnosed by open surgical biopsy after endoscopic ultrasound fine-needle aspiration failed to yield diagnosis: case reports by Reishi Toshiyama et al.
CASE REPORT Open Access
Two cases of resectable pancreatic cancer
diagnosed by open surgical biopsy after
endoscopic ultrasound fine-needle
aspiration failed to yield diagnosis: case
reports
Reishi Toshiyama1, Takehiro Noda1, Hidetoshi Eguchi1* , Yoshifumi Iwagami1, Daisaku Yamada1,
Tadafumi Asaoka1, Hiroshi Wada1, Koichi Kawamoto1, Kunihito Gotoh1, Yutaka Takeda1,4, Masahiro Tanemura1,5,
Eiichi Morii2, Koji Umeshita3, Masaki Mori1 and Yuichiro Doki1
Abstract
Background: Tumor biopsy for histological diagnosis is required preoperatively and before initiating chemotherapy
or radiation therapy for patients with pancreatic cancer (Cancer of the Pancreas: Clinical Practice Guidelines,
European Society for Medical Oncology). Endoscopic ultrasound fine-needle aspiration (EUS-FNA) is widely applied
to obtain tissue samples for histological examination. However, in some cases, EUS-FNA cannot be performed safely
or tissue samples are insufficient to establish a definitive diagnosis. We present two cases of pancreatic cancer
diagnosed by open surgical biopsy after EUS-FNA failed to yield a diagnosis.
Case presentation: Case 1 was a 50-year-old man. Computed tomography showed a hypovascular lesion in the
uncus of the pancreas. Although EUS-FNA was conducted twice, we could not collect enough quantity of tissue
samples to establish a definitive diagnosis. Open surgical biopsy revealed adenocarcinoma, and the patient
underwent preoperative chemoradiation therapy followed by curative operation. Case 2 was a 68-year-old man.
Computed tomography showed a hypovascular tumor in the uncus of the pancreas. EUS revealed a 14-mm
hypoechoic lesion, but we could not perform EUS-FNA because the superior mesenteric vein was located in the
puncture line. Open surgical biopsy revealed adenocarcinoma, and the patient underwent preoperative
chemoradiation therapy followed by pancreaticoduodenectomy.
Conclusions: EUS-FNA is the first choice in the diagnostic modalities of pancreatic neoplasm, but open surgical
biopsy is an effective diagnostic method if EUS-FNA is unsuccessful.
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Background
The prognosis for pancreatic cancer is extremely poor,
and the 5-year survival rate is only approximately 5%
[1]. Pancreatic cancer is the fourth most fatal cancer in
Western countries [2] and the fifth most common cause
of death from cancer in Japan [3]. Surgical resection re-
mains the only potentially curative therapy [4]. However,
only 20% of patients with pancreatic cancer receive cura-
tive resection because most of them show either meta-
static or locally advanced disease in the asymptomatic
phase [5]. In 2015, the European Society for Medical
Oncology (ESMO) published clinical practice guidelines
for cancer of the pancreas and delineated the process for
diagnostic work-ups. They recommended that computed
tomography (CT) was firstly used to determine the
tumor size and precise burden, as well as arterial and
venous local involvement. Tumor biopsy was indicated
for patients who required a histological diagnosis of ma-
lignant disease, not only preoperatively but also before
initiating chemotherapy or chemoradiation therapy
(CRT). Endoscopic ultrasound (EUS) is also widely ap-
plied to obtain tissue samples from primary lesions via
fine-needle aspiration (FNA). The diagnostic accuracy of
EUS-FNA is approximately 90% with histological con-
firmation of malignancy [6–8]. The contents listed in
the National Comprehensive Cancer Network Clinical
Practice Guidelines in Oncology (NCCN guidelines) ver-
sion 2.2016 are similar to ESMO guidelines. The NCCN
guidelines also recommend that neoadjuvant chemother-
apy is considered for patients with high-risk features
such as highly elevated carbohydrate antigen 19-9
(CA19-9) levels, large primary tumors, large regional
lymph nodes, excessive weight loss, and extreme pain.
The pathological diagnosis is also recommended to be
necessary before neoadjuvant chemotherapy or CRT.
However, in some patients, EUS-FNA cannot be per-
formed safely because blood vessels or the main pancre-
atic duct are located along the puncture route or
because the lesion cannot be detected by EUS [9, 10].
Moreover, tissue samples obtained by FNA are insuffi-
cient to establish a definitive diagnosis in some cases.
The core needle biopsy (CNB) provides a sufficiently
large tissue sample, and open surgical biopsy can be per-
formed after multiple attempts such as EUS-FNA are
unsuccessful [11]. Herein, we present two patients with
resectable pancreatic cancer who were diagnosed by
open surgical biopsy after EUS-FNA failed to establish a
diagnosis.
Case presentations
Case 1: A 50-year-old man presented to our hospital
with nausea. He had elevated duke pancreatic monoclo-
nal antigen type 2 (DUPAN-2) levels (680 U/ml), but
carcinoembryonic antigen (CEA) and CA19-9 levels
were within normal limits. Abdominal contrast-
enhanced CT (CECT) revealed a hypovascular lesion in
the uncus of the pancreas (Fig. 1a). The main pancreatic
duct showed stenosis around the tumor. Positron emis-
sion tomography-CT (PET-CT) revealed that fluorine‑18
fluorodeoxyglucose (18 F-FDG) accumulation was with
normal limits (Fig. 1b), but EUS detected a 22 × 15 mm
hypoechoic lesion. EUS-FNA was conducted twice with
a 25-gauge puncture needle (Fig. 1c). Figure 2a, b
showed the specimen obtained by EUS-FNA, but the
Fig. 1 Radiological and endoscopic ultrasonographic findings for case 1. a CECT revealed a hypovascular tumor in the uncus of the pancreas (red
circle). b PET-CT revealed that 18 F-FDG accumulation was within normal range. c EUS revealed a 22-mm hypoechoic lesion in the uncus of the
pancreas (red arrows)
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specimen contained large quantities of blood clots
(Fig. 2a). Microscopically, the findings of enlarged nuclei
and disordered ductal structures were observed (Fig 2b).
However, the quantity of tissue sample was insufficient
to diagnose adenocarcinoma. The tumor was strongly
suspected to be malignant disease based on radiological
findings, and so we performed intraoperative pancreas
biopsy with the Bard® Magnum® Reusable Core Biopsy
Instrument (C. R. Bard, Inc., Murray Hill, NJ, USA).
Firstly, we used 20-gauge × 200 mm puncture needle for
intraoperative biopsies, but the quantity of tumor in the
samples was insufficient, so we changed this needle to
thicker ones (18 gauge and 16 gauge). In performing in-
traoperative biopsy, the important thing was that we
should puncture the mass as perpendicularly as possible.
Finally, the samples obtained by needle of 16 gauge were
sufficient for intraoperative diagnosis.
Intraoperative pancreas biopsy revealed that the
specimen had abundant dyskaryotic cells with nuclear
enlargement. Its ductal structure was disordered, and p53-
positive cells were observed. These findings were consist-
ent with a diagnosis of adenocarcinoma (Fig. 2c, d).
Consequently, we performed preoperative CRT (radiation:
50.5 Gy, chemotherapy: gemcitabine and S-1) and pan-
creaticoduodenectomy (PD). The pathological diagnosis
was invasive ductal adenocarcinoma, and the pathological
stage was pT1N0M0 stage I according to the American
Joint Committee on Cancer (AJCC)/Union for Inter-
national Cancer Control (UICC) seventh edition staging
system. The therapeutic effect of preoperative CRT was
grade IIa according to the Evans classification system [12].
The patient received adjuvant chemotherapy with S-1
(120 mg/day) for 6 months after the operation. Nine
months after the operation, CECT revealed regional
lymph node recurrence and the patient was treated with
systemic chemotherapy (gemcitabine and nab-paclitaxel).
Case 2: A 68-year-old man presented to our hospital
with elevated CA19-9 levels. The patient had a history of
gastric cancer and had been treated by distal gastros-
tomy and Roux-en Y reconstruction. The patient’s
CA19-9 level was 132 U/ml, and CECT revealed a com-
mon bile duct stone and an 8-mm hypovascular tumor
in the uncus of the pancreas (Fig. 3a). The elevated
CA19-9 level was transient, and it suggested that the ele-
vation of CA19-9 had been caused by the inflammation
in the bile duct. We then performed a double balloon
endoscopic retrograde cholangiopancreatography (DB-
ERCP), but we were unable to identify the ampulla of
Vater due to the postoperative status of the Roux-en Y
reconstruction. PET-CT revealed FDG accumulation
(SUVmax 5.6) at the lesion in the uncus (Fig. 3b). EUS
detected a 14 × 12 mm hypoechoic lesion in the uncus,
but we could not perform EUS-FNA because the super-
ior mesenteric vein was located in the puncture line
(Fig. 3c). Therefore, we performed an intraoperative
pancreas biopsy. As similar with case 1, we started
intraoperative biopsies by 20-gauge needle, but finally
we needed 16-gauge needle. The specimen showed
Fig. 2 Pathological analysis by EUS-FNA compared to open surgical biopsy in case 1. a Macroscopic view of specimen obtained by EUS-FNA. The
specimen contained large quantities of blood clots. b Microscopic view of specimen (×100 magnification) revealed enlarged nuclei and disordered
ductal structures. c Specimen obtained by open surgical biopsy. Most of the specimen consisted of pancreatic parenchyma. d Microscopic
view of specimen obtained by open surgical biopsy (×100 magnification) revealed abundant dyskaryotic cells with enlarged nuclei, disordered
ductal structures
Toshiyama et al. Surgical Case Reports  (2017) 3:39 Page 3 of 6
abundant dyskaryotic cells with enlarged nuclei and
atypical, irregular ductal structures. These observations
were consistent with adenocarcinoma (Fig. 4a, b). The
patient received preoperative CRT (radiation: 50.5 Gy,
chemotherapy: gemcitabine and S-1) and underwent PD.
After the operation, the patient’s pathological stage was
pT3N1M0 stage IIB. Three months after the operation,
follow-up CECT revealed a 2-cm irregular lesion in seg-
ment 6 and 7 of the liver, and we diagnosed a tumor re-
currence in the liver. Consequently, the patient
underwent systemic chemotherapy with gemcitabine and
nab-paclitaxel at the frequency once in 2 weeks.
Conclusions
The ESMO clinical guidelines for cancer of the pancreas
state that histological diagnosis by tumor biopsy is indi-
cated for patients before initiating chemotherapy or
CRT. EUS-FNA is routinely performed to diagnose pan-
creatic malignancy. The sensitivity and specificity of
EUS-FNA for pancreatic neoplasms are reported as 64–
85 and 90–100%, respectively [9, 13], and the diagnostic
accuracy is reported as 78–95% [7, 8]. However, FNA
usually yields a small volume of tissue, and in some
cases, it is insufficient for definitive diagnosis. Moreover,
EUS-FNA cannot be performed safely when the artery,
portal vein, or main pancreatic duct fall within the punc-
ture route. The success rate of EUS-FNA depends upon
the experience of the endoscopists [14]. Recent advances
in laparoscopic surgical techniques have enabled
ultrasonography-guided laparoscopic biopsy [15], but
peritoneal dissemination after biopsy has been observed
in some cases. Maemura et al. reported peritoneal dis-
semination in four out of 25 cases after laparoscopic
ultrasonography-guided CNB [16]. And the port site
Fig. 3 Radiological and endoscopic ultrasonographic findings in case 2. a CECT revealed an 8-mm hypovascular tumor in the uncus of the pancreas. b
PET-CT showed FDG accumulation (SUVmax 5.6) corresponding with the pancreas tumor. c EUS detected a 14 × 12-mm hypoechoic lesion in
the uncus, but we could not perform EUS-FNA because the superior mesenteric vein was located in the puncture line
Fig. 4 Pathological analysis by open surgical biopsy in case 2. a The biopsy specimen had dyskaryotic cells with enlarged nuclei and atypical
irregular ductal structures. b Microscopic view of specimen (×100 magnification)
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peritoneal metastasis could occur after laparoscopic
biopsy for pancreatic cancer. However, ultrasonography-
guided laparoscopic biopsy may be useful for unresect-
able or metastatic pancreatic cancer when methods such
as EUS-FNA or percutaneous or CT-guided biopsy have
failed to establish a diagnosis. The utility of making a
preoperative or pretreatment diagnosis in patients with
resectable pancreatic cancer remains controversial. The
method of open surgical biopsy is a popular option for
the diagnosis of resectable pancreatic cancer after other
modalities fail.
Open surgical biopsy for pancreatic neoplasms started
to be conducted around 1960. The complication rate, in-
cluding bleeding, hematoma, wound infection, and pan-
creatitis, was reported as 6.2–13.6% [17–20], and the
sensitivity was 50–78% [19, 20]. In these reports, a 12-
gauge Vim–Silverman needle was used to make the
puncture. From previous reports, we speculated that
thick needle of 12 gauge caused complications after
open surgical biopsy. Then, we started the thinnest
puncture needle (20 gauge) for first puncture. In another
point, we ordered the pathological evaluation for each
samples obtained by each procedures, and when tumor
samples were insufficient to establish a definitive diagno-
sis, we re-tried the puncture by thicker needle. In the
present report, we did not observe any complications
after open surgical biopsy.
There are a number of reports regarding the effect-
iveness of preoperative CRT for pancreatic cancer
[21–23]. Hoffman et al. reported that preoperative
CRT followed by surgical resection resulted in tumor-
free resection margins and longer survival after the
resection. Breslin et al. reported that preoperative
CRT combined with PD prolonged survival and lower
tumor recurrence rate. Our study group conducted
phase I clinical trial of preoperative CRT (gemcitabine
and S-1) for resectable pancreatic cancer and demon-
strated that the regimen of preoperative CRT was
feasible and well tolerated [24]. According to the
Evans classification of the therapeutic effects of pre-
operative CRT, the patients in this report demon-
strated pathological antitumor effects of grades IIa
and IIb, respectively. Based on the results of the
phase I trial, we are now conducting a phase II trial
of preoperative CRT for resectable pancreatic cancer.
Both of the patients described in this report were en-
rolled in this phase II trial.
In summary, we report two cases of patients with pan-
creatic cancer who underwent open surgical biopsy be-
cause EUS-FNA failed to yield a definitive pathological
diagnosis. EUS-FNA is the first choice of diagnostic
modalities for pancreatic neoplasms, but open surgical
biopsy can be considered as an effective diagnostic
method if EUS-FNA is unsuccessful.
Abbreviations
18 F-FDG: Fluorine‑18 fluorodeoxyglucose; AJCC: American Joint Committee
on Cancer; CA19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic
antigen; CECT: Contrast-enhanced CT; CNB: Core needle biopsy;
CRT: Chemoradiation therapy; CT: Computed tomography; DB-ERCP: Double
balloon endoscopic retrograde cholangiopancreatography; DUPAN-2: Duke
pancreatic monoclonal antigen type 2; ESMO: European Society for Medical
Oncology; EUS-FNA: Endoscopic ultrasound fine-needle aspiration; NCCN
guidelines: National Comprehensive Cancer Network Clinical Practice
Guidelines in Oncology; PD: Pancreaticoduodenectomy; PET-CT: Positron
emission tomography-CT; UICC: Union for International Cancer Control
Authors’ contributions
RT drafted the manuscript. TN and HE participated in treating the patients
and revised the manuscript. YI, DY, TA, HW, KK, KG, YT and MT participated in
the surgery and postoperative management. EM investigated these cases
pathologically. UK, MM and DY were responsible for this paper. All of the
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the families of the patients for
publication of these cases and any accompanying images.
Author details
1Department of Gastroenterological Surgery, Graduate School of Medicine,
Osaka University, 2-2 Yamadaoka E-2, Suita, Osaka 565-0871, Japan.
2Department of Pathology, Graduate School of Medicine, Osaka University,
Osaka, Japan. 3Department of Health Sciences, Graduate School of Medicine,
Osaka University, Osaka, Japan. 4Department of Surgery, Kansai Rosai
Hospital, Hyogo, Japan. 5Department of Surgery, Osaka Police Hospital,
Osaka, Japan.
Received: 27 December 2016 Accepted: 22 February 2017
References
1. Schoffel N, Krempel M, Bundschuh M, Bendels MH, Bruggmann D,
Groneberg DA. Pancreatic cancer—critical examination of the Global
Research Architecture and Recent Scientific Developments. Pancreas. 2016;
45(10):1378–85.
2. Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer
mortality predictions for the year 2014. Ann Oncol. 2014;25(8):1650–6.
3. Watanabe J, Otani S, Sakamoto T, Arai Y, Hanaki T, Amisaki M, et al.
Prognostic indicators based on inflammatory and nutritional factors after
pancreaticoduodenectomy for pancreatic cancer. Surg Today. 2016;46(11):
1258–67.
4. Nitta T, Nakamura T, Mitsuhashi T, Asano T, Okamura K, Tsuchikawa T, et al.
The impact of margin status determined by the one-millimeter rule on
tumor recurrence and survival following pancreaticoduodenectomy for
pancreatic ductal adenocarcinoma. Surg Today. 2016. doi:10.1007/s00595-
016-1420-7.
5. Watanabe Y, Nishihara K, Matsumoto S, Okayama T, Abe Y, Nakano T. Effect
of postoperative major complications on prognosis after pancreatectomy
for pancreatic cancer: a retrospective review. Surg Today. 2016. doi:10.1007/
s00595-016-1426-1.
6. Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goere D, et al.
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v56–68.
7. Yoshinaga S, Suzuki H, Oda I, Saito Y. Role of endoscopic ultrasound-guided
fine needle aspiration (EUS-FNA) for diagnosis of solid pancreatic masses.
Dig Endosc. 2011;23 Suppl 1:29–33.
8. Itoi T, Sofuni A, Itokawa F, Irisawa A, Khor CJ, Rerknimitr R. Current status of
diagnostic endoscopic ultrasonography in the evaluation of pancreatic mass
lesions. Dig Endosc. 2011;23 Suppl 1:17–21.
9. Yamao K, Sawaki A, Mizuno N, Shimizu Y, Yatabe Y, Koshikawa T.
Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNAB):
past, present, and future. J Gastroenterol. 2005;40(11):1013–23.
Toshiyama et al. Surgical Case Reports  (2017) 3:39 Page 5 of 6
10. Hawes RH. Indications for EUS-directed FNA. Endoscopy. 1998;30 Suppl 1:
A155–7.
11. Roy A, Kim M, Hawes R, Varadarajulu S. Changing trends in tissue
acquisition in malignant pancreatic neoplasms. J Gastroenterol Hepatol.
2016;31(2):501–5.
12. Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, et al.
Preoperative chemoradiation and pancreaticoduodenectomy for
adenocarcinoma of the pancreas. Arch Surg. 1992;127(11):1335–9.
13. Bhutani MS, Suryaprasad S, Moezzi J, Seabrook D. Improved technique for
performing endoscopic ultrasound guided fine needle aspiration of lymph
nodes. Endoscopy. 1999;31(7):550–3.
14. Lin LF, Tung JN. Experience of endoscopic ultrasound-guided fine needle
aspiration in a regional teaching hospital. Indian J Gastroenterol. 2008;27(4):
156–8.
15. Strasberg SM, Middleton WD, Teefey SA, McNevin MS, Drebin JA. Management
of diagnostic dilemmas of the pancreas by ultrasonographically guided
laparoscopic biopsy. Surgery. 1999;126(4):736–41. discussion 41-3.
16. Maemura K, Shinchi H, Mataki Y, Kurahara H, Iino S, Sakoda M, et al.
Assessment of percutaneous laparoscopic ultrasonography-guided core
needle biopsy for the advanced diagnosis of unresectable pancreatic
cancer. Jop. 2015;16(1):45–9.
17. Forsgren L, Orell S. Aspiration cytology in carcinoma of the pancreas.
Surgery. 1973;73(1):38–42.
18. Isaacson R, Weiland LH, McIlrath DC. Biopsy of the pancreas. Arch Surg.
1974;109(2):227–30.
19. Lightwood R, Reber HA, Way LW. The risk and accuracy of pancreatic
biopsy. Am J Surg. 1976;132(2):189–94.
20. McLoughlin MJ, Ho CS, Tao LC. Percutaneous needle aspiration biopsy.
Can Med Assoc J. 1978;119(11):1324–8.
21. Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, et al.
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas:
treatment variables and survival duration. Ann Surg Oncol. 2001;8(2):123–32.
22. Golcher H, Brunner T, Grabenbauer G, Merkel S, Papadopoulos T,
Hohenberger W, et al. Preoperative chemoradiation in adenocarcinoma of
the pancreas. A single centre experience advocating a new treatment
strategy. Eur J Surg Oncol. 2008;34(7):756–64.
23. Hoffman JP, Weese JL, Solin LJ, Engstrom P, Agarwal P, Barber LW, et al. A pilot
study of preoperative chemoradiation for patients with localized
adenocarcinoma of the pancreas. Am J Surg. 1995;169(1):71–7. discussion 7-8.
24. Eguchi H, Nagano H, Kobayashi S, Kawamoto K, Wada H, Hama N, et al. A
phase I trial of combination therapy using gemcitabine and S-1 concurrent
with full-dose radiation for resectable pancreatic cancer. Cancer Chemother
Pharmacol. 2014;73(2):309–15.
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Toshiyama et al. Surgical Case Reports  (2017) 3:39 Page 6 of 6
